Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the June 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago.

Wall Street analysts forecast that Biogen Inc. (BIIB) will report quarterly earnings of $3.32 per share in its upcoming release, pointing to a year-over-year decline of 9.5%. It is anticipated ...

Biogen Inc (NASDAQ:BIIB) reported a strong start to the year with a significant increase in revenue from new product launches, contributing to 45% of product revenue. The company received FDA Fast ...

AMGN is scheduled to report first-quarter results on May 1, after market close. BIIB’s performance has been strong, with earnings beating estimates in each of the trailing four quarters.

SAGE markets its new depression drug Zurzuvae (zuranolone) in partnership with drug giant Biogen BIIB. Zurzuvae, the first and only oral treatment indicated for adults with postpartum depression ...

While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to ...

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results , with sales up 6.1% year on year to $2.43 billion. Its ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Hsbc Global Res from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Biogen (NASDAQ:BIIB) lowered its full-year outlook to reflect the impact of a $165 million upfront transaction payment to ...